Genetic test to match treatment for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney cancer (clear cell type) confirmed by pathology (biopsy/surgery tissue results).
- Your cancer is advanced or has spread (metastatic) and cannot be cured with surgery or radiation.
- You have not had any drug treatment for kidney cancer before in the advanced/metastatic setting.
- Your scans show at least one measurable spot the doctors can track on treatment.
- You can provide tumor tissue for RNA testing, and it must come from suitable soft tissue around bone (bone-only tissue is not accepted).
- Your general health is good enough (Karnofsky performance score of 70% or higher), and your blood tests and organ function meet limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
This study tests a combination of two drugs (toripalimab and axitinib) as the first treatment for advanced kidney cancer that has clear cell features. The goal is to see if this drug combo can shrink tumors and possibly allow some patients to avoid or delay surgery to remove the kidney. Participation requires a tumor biopsy that shows a specific immune pattern.
This trial tests a new treatment using a patient's own immune cells, called CAR-NKT cells, which are designed to target and attack kidney cancer cells that have a specific marker called CD70. It may be an option for people whose clear cell kidney cancer has come back or spread after at least one prior treatment.
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
Hear when a new Advanced Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.